Sustiva 600 mg p.o.
Videx 550 mg q day.
Bactrim DS one tab q o.d.
Veriad 300 mg q day.
Never used intravenous drug abuse.
PERTINENT LABORATORY ON ADMISSION:  The patient's catheterization report showed 51% ejection fraction, anterior apical hypokinesis, 30% mid-RCA and 100% mid-LAD lesion status post Hepicoat Stent.
The patient was found to have 100% mid-LAD lesion which was intervened with a Hepicoat stent placement.
The patient was placed on Integrulen for 18 hours and was also started on Plavix and aspirin.
The patient additionally for these risk factors was started on statin and ace inhibitor for ventricular remodeling.
The patient had an echocardiogram done which showed apical hypokinesis and therefore was started on Coumadin.
Secondary to INR being subtherapeutic the patient was bridged with Lovenox and Coumadin at the same time but the plan for Lovenox to be discontinued when Coumadin is therapeutic.
The patient was also encouraged to quit tobacco with nicotine patch.
The patient was stable on anti-retrovirals and Bactrim for prophylaxis.
CONDITION ON DISCHARGE:  The patient was stable on discharge and was discharged to home off all oxygen and chest pain free.
Aspirin 325 mg a day.
Plavix 75 mg a day.
Nortovostatin 10 mg a day.
Bactrim one tab p.o.
Didanosine 250 mg p.o.q  day.
Tenofovir 300 mg p.o.
Nitroglycerin 0.3 mg tabs sublingual p.r.n.
Warfarin 5 mg p.o.
Lisinopril 5 mg p.o.
Lovenox 60 mg subcutaneously q 12 h. 11.
Metoprolol 25 mg p.o.
